Your AI-Trained Oncology Knowledge Connection!

Navigating Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory : Episode 14

Opinion

Video

February 25, 2025

Novel Bispecific Antibodies in Development for Relapsed/Refractory Multiple Myeloma

Panelists briefly discuss the results of studies evaluating additional bispecific regimens in the later-stage relapsed/refractory multiple myeloma space, including cevostamab, ABBV-383 plus daratumumab-dexamethasone (Dd), and linvoseltamab in the LINKER-MM1 trial.

EP: 1.Emerging Updates in Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Discussion of the CEPHEUS Trial.

EP: 2.Quadruplet Regimens as Front-Line Therapy for Newly Diagnosed Transplant-Ineligible Multiple Myeloma

EP: 3.Academic Perspectives in Front-Line Treatment Goals in Newly Diagnosed Transplant-Ineligible Multiple Myeloma

EP: 4.Future Considerations for Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

EP: 5.CAR T and Evolving Treatment Paradigms for Early R/R MM

EP: 6.Expert Perspectives: Referrals and Present Challenges with CAR T for Early R/R MM

EP: 7.Optimal Strategies for Bridging Therapy for Patients Receiving CAR T in Early R/R MM

EP: 8.Cilta-Cel in Early R/R MM: Evolving CAR T Data from CARTITUDE-4

EP: 9.CAR T in Early R/R MM: Advances in Ide-Cel From the KarMMa-3 Trial

EP: 10.Weighing CAR T Toxicity Profiles in Early R/R MM

EP: 11.The Evolving Landscape: CAR T and Future Therapies in Early-Stage R/R Myeloma

EP: 12.Treatment Overview in Later-Stage Relapsed/Refractory Multiple Myeloma

EP: 13.Recent Insights Into Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Now Viewing

EP: 14.Novel Bispecific Antibodies in Development for Relapsed/Refractory Multiple Myeloma

EP: 15.Future Treatment Considerations for Multiple Myeloma

Video content above is prompted by the following:

Briefly discuss results from the following studies, evaluating additional bispecific regimens in the later-stage R/R MM space.
Cevostamab in R/R MM:
ABBV-383-Dd in R/R MM:
Linvoseltamab in R/R MM in LINKER-MM1

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity

Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity

Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity

Latest Conference Coverage

Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

Application of Real-World Evidence in Selecting CAR T in R/R MM

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Following ASCT

Apalutamide Boosts 24-Month OS in Real-World Population With Metastatic Castration-Sensitive Prostate Cancer

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Novel Bispecific Antibodies in Development for Relapsed/Refractory Multiple Myeloma

EP: 1.Emerging Updates in Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Discussion of the CEPHEUS Trial.

EP: 2.Quadruplet Regimens as Front-Line Therapy for Newly Diagnosed Transplant-Ineligible Multiple Myeloma

EP: 3.Academic Perspectives in Front-Line Treatment Goals in Newly Diagnosed Transplant-Ineligible Multiple Myeloma

EP: 4.Future Considerations for Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

EP: 5.CAR T and Evolving Treatment Paradigms for Early R/R MM

EP: 6.Expert Perspectives: Referrals and Present Challenges with CAR T for Early R/R MM

EP: 7.Optimal Strategies for Bridging Therapy for Patients Receiving CAR T in Early R/R MM

EP: 8.Cilta-Cel in Early R/R MM: Evolving CAR T Data from CARTITUDE-4

EP: 9.CAR T in Early R/R MM: Advances in Ide-Cel From the KarMMa-3 Trial

EP: 10.Weighing CAR T Toxicity Profiles in Early R/R MM

EP: 11.The Evolving Landscape: CAR T and Future Therapies in Early-Stage R/R Myeloma

EP: 12.Treatment Overview in Later-Stage Relapsed/Refractory Multiple Myeloma

EP: 13.Recent Insights Into Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

EP: 14.Novel Bispecific Antibodies in Development for Relapsed/Refractory Multiple Myeloma

EP: 15.Future Treatment Considerations for Multiple Myeloma

Newsletter

Latest CME

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Latest Conference Coverage